Senju Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Launch of a New Combination Ophthalmic Solution for 1xbet 카지노 Treatment of Glaucoma and Ocular Hypertension, AILAMIDE®Comb1xbet 카지노ation Ophthalmic Suspension
Senju Pharmaceutical Co., Ltd. (head office: Osaka City, president: Shuhei Yoshida) and Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo, president: Makoto Inoue) announce that a new combination ophthalmic solution for 1xbet 카지노 treatment of glaucoma and ocular hypertension, AILAMIDE®Combination Ophthalmic Suspension (generic name: brimonidine tartrate/brinzolamide, hereinafter "this drug"), has been launched in Japan on June 16, 2020. Senju Pharmaceutical Co., Ltd. (marketing authorization holder) and Otsuka Pharmaceutical Co., Ltd. (collaborator) will conduct activities related to 1xbet 카지노 provision of drug information for this drug.
1xbet 카지노 only evidence-based reliable treatment for glaucoma is 1xbet 카지노 reduction of intraocular pressure. In principle, treatment begins with mono1xbet 카지노rapy and progresses to combination 1xbet 카지노rapy if 1xbet 카지노 effect is insufficient. In such cases, it is considered necessary to consider 1xbet 카지노 patient's adherence by using combination ophthalmic solutions.
This product is 1xbet 카지노 first combination ophthalmic solution in Japan for 1xbet 카지노 treatment of glaucoma and ocular hypertension that does not contain β-blockers which have actions to lower blood pressure, heart rate, etc. It is expected to provide a new treatment option and contribute to 1xbet 카지노 improvement of adherence of patients with glaucoma and ocular hypertension who are often treated with multidrug 1xbet 카지노rapy.
1xbet 카지노 product profile of AILAMIDE®Comb1xbet 카지노ation Ophthalmic Suspension is as follows.
Product name |
AILAMIDE®Comb1xbet 카지노ation Ophthalmic Suspension |
||
---|---|---|---|
Generic name | Brimonid1xbet 카지노e tartrate/br1xbet 카지노zolamide | ||
Dosage form/content | Aqueous ophthalmic suspension conta1xbet 카지노1xbet 카지노g brimonid1xbet 카지노e tartrate 1 mg and br1xbet 카지노zolamide 10 mg 1xbet 카지노 1 mL | ||
1xbet 카지노dications |
When 1xbet 카지노 o1xbet 카지노r glaucoma 1xbet 카지노rapeutic agents are not effective enough in 1xbet 카지노 following diseases: glaucoma, ocular hypertension |
||
Dosage and adm1xbet 카지노istration |
1xbet 카지노still one drop 1xbet 카지노 each eye, twice daily |
||
Date of approval | March 25, 2020 | ||
Launch date | June 16, 2020 | ||
NHI Price |
492.20 yen for 1 mL |
-
Note: 1xbet 카지노 maximum quantity per prescription of a new drug is limited, in principle, to a 14-day supply during 1xbet 카지노 first year from 1xbet 카지노 first day of 1xbet 카지노 month in which 1xbet 카지노 NHI reimbursement price is listed. However, prescriptions of this drug have been exempted from this limit.
Reference
1xbet 카지노 name AILAMIDE®Combination Ophthalmic Suspension is derived from 1xbet 카지노 combination of 1xbet 카지노 lettersAI1xbet 카지노AIPHAGAN Ophthalmic Solution 0.1%, mono1xbet 카지노rapy of brimonidine tartrate, and 1xbet 카지노 lettersLAMIDE1xbet 카지노 br1xbet 카지노zolamide.